It's not as though there hasn't been (unpunished) medical fraud before.
https://palexander.substack.com/p/tamiflu-neuraminidase-inhibitors?utm_source=substack&utm_medium=emailTAMIFLU (neuraminidase inhibitors zanamivir (Relenza) and especially oseltamivir (Tamiflu)) for the H5N1 avian influenza in 2004; remember that? TAMIFLU was the fraud drug by pharma, crooked pharma
What did the evidence find? It found that Tamiflu is garbage, junk, and a fraud; we were all deceived, Tamiflu was a drug in search of a disease and they found one, same as Remdesivir found COVID
59 min ago
You have to read the work by Heneghan, Jefferson, and Doshi et al. to see the proper done reviews showing the tamiflu drug fraud. I was stunned for when I put my purist evidence-based medicine hat on, it was clear America and the world was defrauded by pharma and academia once again with the tamiflu lies.
Evidence of the Tamiflu fraud?
For example, ‘recommendations were based on a 2003 pooled analysis by Laurent Kaiser and colleagues, which was based on 10 randomized controlled trials, of which only two had been published. [63] Most of the data supporting oseltamivir’s claim to reduce lower respiratory tract complications had never seen the light of day (another example of Big Pharma playing the fraudulent Disinformation Playbook). The BMJ and Cochrane reviewers contacted the authors of the 2003 paper but were told they did not have the data on the missing eight studies. [62] So the Cochrane team went to the source, the manufacturer, Roche. The company refused to release the data unless the reviewers signed a confidentiality agreement with a secrecy clause. [62] This they weren’t prepared to do, as it could stop them reporting their findings. So began a campaign of public pressure that lasted four years.
A freedom of information request shook loose 20,000 pages of incomplete oseltamivir data from the European Medicines Agency in 2011. Later in 2011, Roche finally relented and released 77 full clinical study reports of oseltamivir trials. Importantly, none of the trials was independent of the drug’s manufacturer; in addition, all were against placebo rather than against standard drugs for relieving symptoms, such as acetaminophen. [65] Furthermore, many of the published studies were ghost-written and in many instances it was impossible to work out who actually carried out the research. [65;66]
A Cochrane review in 2014 that used the newly released data found insufficient evidence to support claims that oseltamivir reduced lower respiratory tract complications or impeded viral transmission. [67;68] There was no significant reduction in risk of pneumonia, bronchitis, otitis media, sinusitis, or any complication classified as serious and no reduction in the risk of hospitalization. The reviewers also raised new questions about the drug’s harm profile; the use of oseltamivir increases the risk of nausea, vomiting, psychiatric events in adults, and vomiting in children.
An additional analysis demonstrated that Oseltamivir had no protective effect on mortality among patients with 2009A/H1N1 influenza. [69] Furthermore, data suggests that Tamiflu does not have antiviral properties but rather acts as an antipyretic (fever reducer). [62] As treatment with Tamiflu only suppresses symptoms, “then infected people could be going to work and school feeling fine, while passing on the flu virus.” [62] Despite these data, pandemic stockpiles are still being scrupulously topped up and the “influenza pandemic” response plans of the UK and US have not changed in over a decade (another example of the Pharma-Government fraudulent collaboration). [62]
Hasan ZT, AlAtrakji MQ, Mehuaiden AK. The effect of melatonin on thrombosis, sepsis and mortality rate in COVID-19 patients. International Journal of Infectious Diseases 2022; 114:79-84.
Farnoosh G, Akbariqomi M, Badri T, Bagheri M, Izadi M, rezaie E. Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patietns with COVID-19: A randomized, double-blind clinical trial. Archives of Medical Research 2021.
Darban M, Malek F, Memarian M, Gohari A, Kiani A, Emadi A. Efficacy of high dose vitamin C, melatonin and zinc in Iranian patients with acute respiratory sydrome due to Coronavirus infection: A pilot randomized trial. Journal of Cellular & Molecular Anesthesia 2021; 6:164-167.
Dyer O. What did we learn from Tamiflu? BMJ 2020; 368:m626.
Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of Oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2002; 163:1667-1672.
The Disinformation Playbook. https://www ucsusa org/resources/disinformation-playbook [ 2018 [cited 2022 Nov. 15];
Loder E, Tovey D, Godlee F. The Tamiflu trials. Progress towards data sharing but many battles still to fight. BMJ 2014; 348:g2630.
Cohen D. Complications: tracking down the data on oseltamivir. BMJ 2009; 339:b5387.
Jones JT, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database of Syst Rev 2014; 4:CD008965.
Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Hama R, Spencer EA et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technology Assessment 2016; 42.
